Entera Bio (ENTX) Receivables (2018 - 2025)

Entera Bio's (ENTX) quarterly Receivables came in at $126000.0 in Q1 2025, little changed on a QoQ basis from $126000.0 in Q4 2024.

Entera Bio (ENTX) Receivables (2018 - 2025) Analysis & Trends

Entera Bio (ENTX) has 8 years of Receivables data on file, last reported at $126000.0 in Q1 2025.

Quarterly Receivables changed N/A year-over-year to $126000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $126000.0 (changed N/A YoY) and the FY2024 annual result came in at $126000.0, changed N/A from the prior year.
Receivables was little changed at $126000.0 in Q1 2025, from $126000.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $246000.0 in Q4 2022 to a low of $29000.0 in Q1 2023.
A 5-year average of $135166.7 and a median of $126000.0 in 2024 frame the typical range for Receivables.
Annual changes were most pronounced in 2023 — Receivables slumped 87.11% — and 2024, when it jumped 96.55%.
Tracing ENTX's Receivables over 5 years: stood at $183000.0 in 2021, then surged by 34.43% to $246000.0 in 2022, then slumped by 88.21% to $29000.0 in 2023, then jumped by 334.48% to $126000.0 in 2024, then changed by 0.0% to $126000.0 in 2025.
The last three Receivables figures came in at $126000.0 (Q1 2025), $126000.0 (Q4 2024), and $42000.0 (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	138.57 Bn	130.72 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.99 Bn	77.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	65.00 Bn	59.82 Bn	1.37 Bn	1.93 Bn
4	Moderna	56.27 Bn	51.13 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	42.00 Bn	36.90 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.60 Bn	28.29 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	27.68 Bn	9.29 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.43 Bn	26.27 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.34 Bn	26.51 Bn	-	-
10	Entera Bio	164.47 Mn	153.16 Mn	-	-

Download Data